The Impassion-130 trial (NCT02425891), in which patients were randomized to receive albumin-bound paclitaxel or albumin-bound paclitaxel plus atezolizumab as a first-line treatment for metastatic triple-negative breast cancer, showed a significant median progression-free survival (PFS) benefit in the immunotherapy group compared to the control group (7.2 months vs. 5.5 months). Here, ALB is linked to triple-negative breast carcinoma.